CDKN2A/B status and histological grade independently predict post-recurrence survival in recurrent IDH-mutant astrocytoma
{{output}}
Homozygous deletions of cyclin-dependent kinase inhibitor 2 A/B (CDKN2A/B) are recognized as poor prognostic markers in newly diagnosed IDH-mutant astrocytomas. However, a standardized definition of CDKN2A/B homozygous deletion has not yet been established. Fu... ...